PT836648E - Virus mva recombinante e sua utilizacao - Google Patents

Virus mva recombinante e sua utilizacao

Info

Publication number: PT836648E
Authority: PT; Portugal
Prior art keywords: recombinant mva; utilization; viruses; mva viruses; recombinant
Prior art date: 1995-07-04

Application number

PT96925654T

Other languages

English (en)

Inventor

Gerd Sutter

Marion Ohlmann

Volker Erfle

Original Assignee

Gsf Forschungszentrum Umwelt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-04

Filing date

1996-07-03

Publication date

2003-09-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT836648(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-03 Application filed by Gsf Forschungszentrum Umwelt filed Critical Gsf Forschungszentrum Umwelt

2003-09-30 Publication of PT836648E publication Critical patent/PT836648E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
- C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
- C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Manufacturing & Machinery (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PT96925654T 1995-07-04 1996-07-03 Virus mva recombinante e sua utilizacao PT836648E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK78295		1995-07-04

Publications (1)

Publication Number	Publication Date
PT836648E true PT836648E (pt)	2003-09-30

Family

ID=8097499

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96925654T PT836648E (pt)	1995-07-04	1996-07-03	Virus mva recombinante e sua utilizacao

Country Status (26)

Country	Link
US (6)	US6440422B1 (pt)
EP (3)	EP1312678B1 (pt)
JP (3)	JP4312260B2 (pt)
KR (1)	KR19990028617A (pt)
CN (3)	CN1782071A (pt)
AT (3)	ATE239796T1 (pt)
AU (1)	AU721735B2 (pt)
BR (1)	BR9609303B8 (pt)
CA (3)	CA2608864C (pt)
CZ (1)	CZ292460B6 (pt)
DE (3)	DE69628011T2 (pt)
DK (3)	DK0836648T3 (pt)
EE (3)	EE04753B1 (pt)
ES (3)	ES2199294T3 (pt)
HU (2)	HU229261B1 (pt)
IL (5)	IL122120A (pt)
MX (1)	MX9800025A (pt)
NO (1)	NO322476B1 (pt)
NZ (1)	NZ313597A (pt)
PL (1)	PL186857B1 (pt)
PT (1)	PT836648E (pt)
RU (1)	RU2198217C2 (pt)
SI (3)	SI1312679T1 (pt)
TW (2)	TW575664B (pt)
UA (3)	UA68327C2 (pt)
WO (1)	WO1997002355A1 (pt)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA68327C2 (en) *	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7118754B1 (en) *	1996-07-30	2006-10-10	Transgene S.A.	Pharmaceutical composition for treating papillomavirus tumors and infection
WO1998013500A2 (en) *	1996-09-24	1998-04-02	Bavarian Nordic Research Institute A/S	Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
MY119381A (en) *	1996-12-24	2005-05-31	Gsf Forschungszentrum Umwelt	Recombinant mva virus, and the use thereof
US6969609B1 (en) *	1998-12-09	2005-11-29	The United States Of America As Represented By The Department Of Health And Human Serivces	Recombinant vector expressing multiple costimulatory molecules and uses thereof
FR2784997A1 (fr) *	1998-10-22	2000-04-28	Transgene Sa	Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
US20040265324A1 (en) *	1999-03-23	2004-12-30	Cardosa Mary Jane	Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
AU5397100A (en) *	1999-05-28	2000-12-18	Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh	Vector for integration of heterologous sequences into poxviral genomes
US20150231227A1 (en) *	2000-03-02	2015-08-20	Emory University	Compositions and methods for generating an immune response
DE60113512T2 (de)	2000-03-14	2006-06-22	Bavarian Nordic A/S	Veränderter stamm des modifizierten vaccinia-virus ankara (mva)
RU2217162C2 (ru) *	2000-04-10	2003-11-27	Государственный научный центр вирусологии и биотехнологии "Вектор"	Вакцина против вирусных инфекций
DE10042598A1 (de) *	2000-08-30	2002-03-28	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
AU2002211654A1 (en) *	2000-10-10	2002-04-22	Genstar Therapeutics	Minimal adenoviral vector and recombinant vaccines based thereon
US7445924B2 (en)	2000-11-23	2008-11-04	Bavarian Nordic A/S	Modified Vaccinia Ankara virus variant and cultivation method
BRPI0115533B8 (pt)	2000-11-23	2021-05-25	Bavarian Nordic As	variação do vírus vaccinia ankara modificado
US7628980B2 (en)	2000-11-23	2009-12-08	Bavarian Nordic A/S	Modified vaccinia virus ankara for the vaccination of neonates
US7740863B2 (en)	2001-04-06	2010-06-22	Merial	Recombinant vaccine against West Nile Virus
DE10143490C2 (de) *	2001-09-05	2003-12-11	Gsf Forschungszentrum Umwelt	Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
DE10144664B4 (de) *	2001-09-11	2005-06-09	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
CN1602316A (zh)	2001-12-04	2005-03-30	巴法里安诺迪克有限公司	黄病毒ns1亚单位疫苗
HU227507B1 (hu) *	2001-12-20	2011-07-28	Bavarian Nordic As	Eljárás poxvírusok kinyerésére és tisztítására fertõzött sejtekbõl
JP4801880B2 (ja)	2002-04-19	2011-10-26	バヴァリアン・ノルディック・アクティーゼルスカブ	新生仔予防接種用変異ワクシニアウイルスアンカラ
EP1404852B1 (en) *	2002-05-16	2005-12-21	Bavarian Nordic A/S	Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
US7501127B2 (en)	2002-05-16	2009-03-10	Bavarian Nordic A/S	Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
US7550147B2 (en)	2002-05-16	2009-06-23	Bavarian Nordic A/S	Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
PL215169B1 (pl)	2002-09-05	2013-10-31	Bavarian Nordic As	Sposób amplifikacji wirusów, kompozycja zawierajaca pokswirusa uzyskanego tym sposobem oraz jego zastosowanie do otrzymywania szczepionki
DE10249390A1 (de) *	2002-10-23	2004-05-13	Ruprecht-Karls-Universität Heidelberg	Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
EP1567653B1 (en)	2002-11-25	2007-06-20	Bavarian Nordic A/S	Recombinant poxvirus comprising at least two cowpox ati promoters
ATE403005T1 (de) *	2003-02-18	2008-08-15	Helmholtz Zentrum Muenchen	Rekombinantes mva und verfahren zur erzeugung davon
EP2363493B1 (en) *	2003-02-20	2012-11-14	The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services	Novel insertion sites in pox vectors
US7731974B2 (en) *	2003-03-27	2010-06-08	Ottawa Hospital Research Institute	Mutant vesicular stomatitis viruses and uses thereof
ATE417115T1 (de)	2003-03-27	2008-12-15	Ottawa Health Research Inst	Mutante vesicular stomatitis viren und deren verwendungen
WO2004093905A1 (en) *	2003-04-16	2004-11-04	City Of Hope	Human cytomegalovirus antigens expressed in mva and methods of use
GB2402391A (en) *	2003-06-04	2004-12-08	Oxxon Pharmaccines Ltd	Fowlpox recombinant genome
DK1648931T3 (da)	2003-07-21	2011-03-07	Transgene Sa	Multifunktionelle cytokiner
WO2005017208A1 (en) *	2003-07-31	2005-02-24	George Mason Intellectual Properties, Inc.	Compositions and methods for treating or preventing hiv infection
EP1518932A1 (en)	2003-09-29	2005-03-30	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Modified vaccinia virus Ankara (MVA) mutant and use thereof
DK1536015T3 (da) *	2003-11-24	2008-02-18	Bavarian Nordic As	Promotorer til ekspression i modificeret vacciniavirus Ankara
EP1710300A4 (en)	2003-12-05	2007-10-24	Hokkaido Tech Licensing Office	HIGHLY SAFE POX VACCINE VIRUS AND VACCINIA VIRUS VECTOR
EP1683870A1 (en) *	2005-01-24	2006-07-26	GSF-Forschungszentrum für Umwelt und Gesundheit GmbH	Vaccines based on the use of MVA
WO2006113927A2 (en) *	2005-04-20	2006-10-26	University Of Washington	Immunogenic vaccinia peptides and methods of using same
EP2023954B1 (en) *	2006-05-19	2013-07-17	Sanofi Pasteur, Inc.	Immunological composition
EP2029756B1 (en) *	2006-06-20	2016-11-09	Transgene S.A.	Process for producing poxviruses and poxvirus compositions
WO2008076157A2 (en) *	2006-09-08	2008-06-26	Duke University	Modified vaccinia ankara virus vaccine
US8481023B2 (en)	2006-09-15	2013-07-09	Ottawa Hospital Research Institute	Oncolytic rhabdovirus
DK2073837T3 (da)	2006-10-06	2014-09-29	Bavarian Nordic Inc	Rekombinant modificeret vaccinia-ankara-virus, der koder for et her-2-antigen, i kombination med en taxan til anvendelse til behandling af cancer
US20080241139A1 (en) *	2006-10-31	2008-10-02	Regents Of The University Of Colorado	Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
EP2117558A4 (en) *	2007-01-26	2013-04-03	Univ Colorado	METHOD FOR MODULATING THE IMMUNO FUNCTION
EP2152736B1 (en)	2007-05-03	2017-07-05	Lysomab GmbH	Complement factor h-derived short consensus repeat-antibody constructs
CA2676149C (en) *	2007-05-14	2016-06-21	Bavarian Nordic A/S	Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003363B2 (en) *	2007-05-14	2011-08-23	Bavarian Nordic A/S	Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
US8003364B2 (en)	2007-05-14	2011-08-23	Bavarian Nordic A/S	Purification of vaccinia viruses using hydrophobic interaction chromatography
US20100285050A1 (en) *	2007-10-05	2010-11-11	Isis Innovation Limited	Compositions and Methods
BRPI0800485B8 (pt) *	2008-01-17	2021-05-25	Univ Minas Gerais	vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
JP2011511640A (ja)	2008-02-12	2011-04-14	サノフィパストゥールリミテッド	ポックス・ウイルスの精製方法
WO2009152969A1 (en) *	2008-06-20	2009-12-23	Bavarian Nordic A/S	Recombinant modified vaccinia virus measles vaccine
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
WO2010127115A1 (en)	2009-04-30	2010-11-04	Centre Hospitalier Universitaire Vaudois Lausanne (Chuv)	Modified immunization vectors
RU2555346C2 (ru) *	2009-08-07	2015-07-10	Трансген Са	Композиция для лечения инфекции вирусом гепатита в
JP5798124B2 (ja) *	2009-11-20	2015-10-21	タケダワクチン, インコーポレイテッドTakeda Vaccines, Inc.	ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物
US9005632B2 (en)	2009-11-20	2015-04-14	Takeda Vaccines, Inc.	Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
AU2011230619C1 (en)	2010-03-25	2016-06-23	Oregon Health & Science University	CMV glycoproteins and recombinant vectors
GB201006405D0 (en)	2010-04-16	2010-06-02	Isis Innovation	Poxvirus expression system
US20110262965A1 (en) *	2010-04-23	2011-10-27	Life Technologies Corporation	Cell culture medium comprising small peptides
WO2012101509A2 (en)	2011-01-28	2012-08-02	Sanofi Pasteur Sa	Immunological compositions against hiv
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
HRP20180607T1 (hr)	2011-06-10	2019-04-05	Oregon Health & Science University	Glikoproteini i rekombinantni vektori cmv
KR102022952B1 (ko) *	2011-08-05	2019-09-20	신라젠(주)	백시니아 바이러스의 생산을 위한 방법 및 조성물
CA2789539A1 (en)	2011-09-12	2013-03-12	International Aids Vaccine Initiative	Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
ES2683820T3 (es) *	2011-09-26	2018-09-28	Theravectys	Uso de proteínas GAG no de subtipo B para encapsidación lentiviral
US9402894B2 (en)	2011-10-27	2016-08-02	International Aids Vaccine Initiative	Viral particles derived from an enveloped virus
WO2013083254A1 (en)	2011-12-09	2013-06-13	Bavarian Nordic A/S	Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en)	2012-01-27	2013-07-31	Laboratorios Del Dr. Esteve, S.A.	Immunogens for HIV vaccination
EP2679596B1 (en)	2012-06-27	2017-04-12	International Aids Vaccine Initiative	HIV-1 env glycoprotein variant
EA029492B1 (ru)	2012-07-10	2018-04-30	Трансген Са	Вакцина на основе микобактериальных антигенов
WO2014009433A1 (en)	2012-07-10	2014-01-16	Transgene Sa	Mycobacterium resuscitation promoting factor for use as adjuvant
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
WO2014066443A1 (en)	2012-10-23	2014-05-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
US20140286981A1 (en) *	2013-03-14	2014-09-25	Wisconsin Alumni Research Foundation	Broadly reactive mosaic peptide for influenza vaccine
DE102013004595A1 (de)	2013-03-15	2014-09-18	Emergent Product Development Germany Gmbh	RSV-Impfstoffe
EP2848937A1 (en)	2013-09-05	2015-03-18	International Aids Vaccine Initiative	Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en)	2013-10-07	2017-05-31	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
WO2015104380A1 (en)	2014-01-09	2015-07-16	Transgene Sa	Fusion of heterooligomeric mycobacterial antigens
GB201412494D0 (en)	2014-07-14	2014-08-27	Ospedale San Raffaele And Fond Telethon	Vector production
EP3868398A1 (en)	2014-09-26	2021-08-25	Beth Israel Deaconess Medical Center, Inc.	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
EP3244919A4 (en)	2015-01-12	2018-06-27	Geovax, Inc.	Compositions and methods for generating an immune response to a hemorrhagic fever virus
WO2016128542A1 (en)	2015-02-13	2016-08-18	Transgene Sa	Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en)	2015-02-20	2016-08-25	Transgene Sa	Combination product with autophagy modulator
EP3069730A3 (en)	2015-03-20	2017-03-15	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en)	2015-03-23	2016-09-28	International Aids Vaccine Initiative	Soluble hiv-1 envelope glycoprotein trimers
MA44059B1 (fr)	2015-12-15	2019-11-29	Janssen Vaccines & Prevention Bv	Antigènes du virus de l'immunodéficience humaine, vecteurs, compositions, et leurs procédés d'utilisation
AU2017206102C1 (en) *	2016-01-08	2022-02-10	Geovax Inc.	Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt)	2016-02-03	2018-12-26	Geovax Inc	composições e métodos para gerar uma resposta imune para um flavivírus
BR112018016948A2 (pt) *	2016-02-25	2019-01-08	Memorial Sloan Kettering Cancer Center	mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos
EP3452081A1 (en)	2016-05-04	2019-03-13	Transgene SA	Combination therapy with cpg tlr9 ligand
CA3027454A1 (en)	2016-06-16	2017-12-21	Janssen Vaccines & Prevention B.V.	Hiv vaccine formulation
CA3035759A1 (en)	2016-09-02	2018-03-08	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
LT3512543T (lt)	2016-09-15	2020-11-10	Janssen Vaccines & Prevention B.V.	Trimerą stabilizuojančios živ apvalkalo baltymo mutacijos
WO2018069316A2 (en)	2016-10-10	2018-04-19	Transgene Sa	Immunotherapeutic product and mdsc modulator combination therapy
BR112019026126A2 (pt)	2017-06-15	2020-06-30	Janssen Vaccines & Prevention B.V.	vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
CA3067405A1 (en)	2017-06-21	2018-12-27	Transgene Sa	Personalized vaccine comprising a recombinant poxvirus expressing a fusioin of nepopeptides
KR20200031655A (ko)	2017-07-19	2020-03-24	얀센 백신스 앤드 프리벤션 비.브이.	삼량체를 안정화하는 hiv 엔벨로프 단백질 돌연변이
US20190022212A1 (en)	2017-07-21	2019-01-24	Beth Israel Deaconess Medical Center, Inc.	Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human
US20190083620A1 (en)	2017-09-18	2019-03-21	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US11311612B2 (en)	2017-09-19	2022-04-26	Geovax, Inc.	Compositions and methods for generating an immune response to treat or prevent malaria
CA3081436A1 (en)	2017-10-31	2019-05-09	Western Oncolytics Ltd.	Platform oncolytic vector for systemic delivery
WO2020051766A1 (zh)	2018-09-11	2020-03-19	上海市公共卫生临床中心	一种广谱抗流感疫苗免疫原及其应用
TW202110476A (zh)	2019-05-22	2021-03-16	荷蘭商傑森疫苗防護公司	於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法
WO2021076998A1 (en) *	2019-10-16	2021-04-22	KaliVir Immunotherapeutics LLC	Producer viruses for generation of retroviruses in situ
CN116322757A (zh)	2019-11-14	2023-06-23	埃利克斯疗法公司	用于疫苗的剂量方案
EP3842065A1 (en)	2019-12-23	2021-06-30	Transgene	Process for designing a recombinant poxvirus for a therapeutic vaccine
EP3928789A1 (en)	2020-06-24	2021-12-29	Consejo Superior de Investigaciones Científicas (CSIC)	Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
WO2021260065A1 (en)	2020-06-24	2021-12-30	Consejo Superior De Investigaciones Científicas (Csic)	Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
CA3197371A1 (en)	2020-11-19	2022-05-27	Kalivir Immunotherapeutics, Inc.	Oncolytic immunotherapy by tumor micro-environment remodeling
PE20250454A1 (es)	2021-04-30	2025-02-19	Kalivir Immunotherapeutics Inc	Virus oncoliticos para la expresion modificada del mhc
EP4108257A1 (en)	2021-06-23	2022-12-28	Consejo Superior De Investigaciones Científicas	Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
EP4358999A1 (en)	2021-06-23	2024-05-01	Consejo Superior De Investigaciones Científicas	Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
WO2023213763A1 (en)	2022-05-02	2023-11-09	Transgene	Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en)	2022-05-02	2023-11-09	Transgene	Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023220283A1 (en)	2022-05-12	2023-11-16	Pellis Therapeutics, Inc.	Poxvirus adjuvant for t-cell vaccination
EP4316514A1 (en)	2022-08-03	2024-02-07	Consejo Superior de Investigaciones Científicas (CSIC)	Mva-based vectors and their use as vaccine against sars-cov-2
IL322666A (en)	2023-03-17	2025-10-01	Helmholtz Zentrum M?Nchen Deutsches Forschungszentrum F?R Gesundheit Und Umwelt Gmbh	A preparation containing HBV antigen for the treatment of hepatitis B
WO2025172435A1 (en)	2024-02-13	2025-08-21	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Hbv antigen formulation for treating hepatitis b

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787901A (fr)	1971-09-11	1972-12-18	Freistaat Bayern Represente Pa	Vaccin antivariolique
AU570940B2 (en)	1982-11-30	1988-03-31	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Process for producing poxvirus recombinants for expression offoreign genes
US5679511A (en) *	1986-10-06	1997-10-21	Donald Guthrie Foundation For Medical Research, Inc.	CDNA clones for a regulatory protein in the melanin-production pathway
CA1341245C (en) *	1988-01-12	2001-06-05	F. Hoffmann-La Roche Ag	Recombinant vaccinia virus mva
US5221610A (en) *	1988-05-26	1993-06-22	Institut Pasteur	Diagnostic method and composition for early detection of HIV infection
CN1042564A (zh) *	1988-11-11	1990-05-30	中国科学院上海生物化学研究所	乙肝疫苗的制备方法及其制品
JPH03271233A (ja)	1990-03-19	1991-12-03	Inst Pasteur	ウイルスエンベロープ糖タンパク質及びその糖タンパク質の中和エピトープに対応するペプチドの間の相乗作用による、ウイルス性感染に対する防御の誘発
CA2122263A1 (en) *	1991-10-28	1993-05-13	Marc Girard	Induction of protection against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
DE69331813T4 (de) *	1992-12-22	2003-07-10	Ludwig Institute For Cancer Research, New York	Verfahren zur Detektion und Behandlung von Individuen mit abnormal hla-a2/tyrosinase-peptidantigenen exprimierenden Zellen
US5620886A (en) *	1993-03-18	1997-04-15	Ludwig Institute For Cancer Research	Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
WO1995011255A1 (en) *	1993-10-19	1995-04-27	Ajinomoto Co., Inc.	Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
US5676950A (en) *	1994-10-28	1997-10-14	University Of Florida	Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) *	1995-07-04	2004-08-16	Gsf Forschungszentrum Fur Unwe	A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals

1996
- 1996-03-07 UA UA97126424A patent/UA68327C2/uk unknown
- 1996-07-03 DK DK96925654T patent/DK0836648T3/da active
- 1996-07-03 HU HU0402350A patent/HU229261B1/hu unknown
- 1996-07-03 EP EP03001378A patent/EP1312678B1/en not_active Expired - Lifetime
- 1996-07-03 JP JP50482497A patent/JP4312260B2/ja not_active Expired - Lifetime
- 1996-07-03 CN CNA2005101248556A patent/CN1782071A/zh active Pending
- 1996-07-03 ES ES96925654T patent/ES2199294T3/es not_active Expired - Lifetime
- 1996-07-03 HU HU9802217A patent/HU224061B1/hu active IP Right Grant
- 1996-07-03 DE DE69628011T patent/DE69628011T2/de not_active Expired - Lifetime
- 1996-07-03 EP EP03001379A patent/EP1312679B8/en not_active Expired - Lifetime
- 1996-07-03 SI SI9630719T patent/SI1312679T1/sl unknown
- 1996-07-03 UA UA20031212890A patent/UA75410C2/uk unknown
- 1996-07-03 ES ES03001379T patent/ES2249648T3/es not_active Expired - Lifetime
- 1996-07-03 EE EEP200300332A patent/EE04753B1/xx unknown
- 1996-07-03 DE DE69635172T patent/DE69635172T2/de not_active Expired - Lifetime
- 1996-07-03 DK DK03001379T patent/DK1312679T3/da active
- 1996-07-03 CZ CZ19974241A patent/CZ292460B6/cs not_active IP Right Cessation
- 1996-07-03 IL IL12212096A patent/IL122120A/xx not_active IP Right Cessation
- 1996-07-03 NZ NZ313597A patent/NZ313597A/xx not_active IP Right Cessation
- 1996-07-03 RU RU98101904/13A patent/RU2198217C2/ru active
- 1996-07-03 AT AT96925654T patent/ATE239796T1/de active
- 1996-07-03 AU AU66110/96A patent/AU721735B2/en not_active Expired
- 1996-07-03 CN CN2004100367144A patent/CN1554764B/zh not_active Expired - Lifetime
- 1996-07-03 AT AT03001378T patent/ATE304057T1/de active
- 1996-07-03 EP EP96925654A patent/EP0836648B1/en not_active Expired - Lifetime
- 1996-07-03 PT PT96925654T patent/PT836648E/pt unknown
- 1996-07-03 EE EE9700344A patent/EE04199B1/xx unknown
- 1996-07-03 CA CA2608864A patent/CA2608864C/en not_active Expired - Lifetime
- 1996-07-03 SI SI9630623T patent/SI0836648T1/xx unknown
- 1996-07-03 DE DE69635173T patent/DE69635173T2/de not_active Expired - Lifetime
- 1996-07-03 MX MX9800025A patent/MX9800025A/es unknown
- 1996-07-03 KR KR1019970709939A patent/KR19990028617A/ko not_active Ceased
- 1996-07-03 UA UA20031212892A patent/UA75411C2/uk unknown
- 1996-07-03 ES ES03001378T patent/ES2249647T3/es not_active Expired - Lifetime
- 1996-07-03 CA CA002225278A patent/CA2225278C/en not_active Expired - Lifetime
- 1996-07-03 DK DK03001378T patent/DK1312678T3/da active
- 1996-07-03 CA CA2596274A patent/CA2596274C/en not_active Expired - Lifetime
- 1996-07-03 SI SI9630718T patent/SI1312678T1/sl unknown
- 1996-07-03 PL PL96324347A patent/PL186857B1/pl unknown
- 1996-07-03 CN CNB961952547A patent/CN1154742C/zh not_active Expired - Lifetime
- 1996-07-03 BR BRPI9609303-0B8A patent/BR9609303B8/pt active IP Right Grant
- 1996-07-03 WO PCT/EP1996/002926 patent/WO1997002355A1/en not_active Ceased
- 1996-07-03 EE EEP200300331A patent/EE05138B1/xx unknown
- 1996-07-03 AT AT03001379T patent/ATE304058T1/de active
- 1996-12-31 TW TW085116379A patent/TW575664B/zh not_active IP Right Cessation
- 1996-12-31 TW TW092116681A patent/TWI245075B/zh not_active IP Right Cessation
1998
- 1998-01-02 NO NO19980026A patent/NO322476B1/no not_active IP Right Cessation
- 1998-01-02 US US09/002,443 patent/US6440422B1/en not_active Expired - Lifetime
2002
- 2002-05-15 US US10/147,284 patent/US7198934B2/en not_active Expired - Fee Related
2004
- 2004-09-28 IL IL164318A patent/IL164318A/en not_active IP Right Cessation
2006
- 2006-09-19 US US11/523,004 patent/US20070071769A1/en not_active Abandoned
- 2006-09-19 US US11/522,889 patent/US8153138B2/en not_active Expired - Fee Related
- 2006-09-19 US US11/523,030 patent/US20070071770A1/en not_active Abandoned
2007
- 2007-03-12 JP JP2007062630A patent/JP4764366B2/ja not_active Expired - Lifetime
- 2007-03-12 JP JP2007062631A patent/JP4764367B2/ja not_active Expired - Lifetime
2009
- 2009-12-01 IL IL202448A patent/IL202448A0/en unknown
2010
- 2010-06-14 US US12/814,602 patent/US8197825B2/en not_active Expired - Fee Related
2011
- 2011-05-17 IL IL212933A patent/IL212933A0/en unknown
2012
- 2012-05-02 IL IL219528A patent/IL219528A0/en unknown

Also Published As

Publication number	Publication date
CA2225278C (en)	2009-01-27
DE69628011T2 (de)	2004-03-18
ATE304057T1 (de)	2005-09-15
EE200300331A (et)	2003-10-15
AU6611096A (en)	1997-02-05
CA2596274C (en)	2010-09-07
ATE239796T1 (de)	2003-05-15
IL122120A0 (en)	1998-04-05
EP1312678B1 (en)	2005-09-07
CA2608864C (en)	2010-09-07
HUP9802217A2 (hu)	1999-01-28
CN1189857A (zh)	1998-08-05
MX9800025A (es)	1998-03-31
NO322476B1 (no)	2006-10-09
EP1312679B8 (en)	2005-11-23
NZ313597A (en)	1999-01-28
IL122120A (en)	2005-07-25
HK1068015A1 (en)	2005-04-22
KR19990028617A (ko)	1999-04-15
ATE304058T1 (de)	2005-09-15
WO1997002355A1 (en)	1997-01-23
US20070071769A1 (en)	2007-03-29
SI0836648T1 (en)	2003-12-31
JPH11509091A (ja)	1999-08-17
DE69635172D1 (de)	2005-10-13
DE69628011D1 (de)	2003-06-12
EP0836648B1 (en)	2003-05-07
JP4764366B2 (ja)	2011-08-31
DK0836648T3 (da)	2003-08-25
EE9700344A (et)	1998-06-15
HU0402350D0 (en)	2005-01-28
ES2249648T3 (es)	2006-04-01
CN1554764A (zh)	2004-12-15
TW575664B (en)	2004-02-11
IL212933A0 (en)	2011-07-31
HU229261B1 (en)	2013-10-28
JP2007252374A (ja)	2007-10-04
PL324347A1 (en)	1998-05-25
CZ292460B6 (cs)	2003-09-17
SI1312678T1 (sl)	2006-02-28
BR9609303A (pt)	1999-05-25
US7198934B2 (en)	2007-04-03
JP2007244382A (ja)	2007-09-27
CA2608864A1 (en)	1997-01-23
IL164318A0 (en)	2005-12-18
NO980026L (no)	1998-01-02
EP1312678A1 (en)	2003-05-21
US20100291139A1 (en)	2010-11-18
CN1554764B (zh)	2012-03-21
TW200305646A (en)	2003-11-01
IL164318A (en)	2013-08-29
BR9609303B1 (pt)	2014-04-08
JP4764367B2 (ja)	2011-08-31
US6440422B1 (en)	2002-08-27
CN1782071A (zh)	2006-06-07
DE69635173T2 (de)	2006-07-13
CA2596274A1 (en)	1997-01-23
US20100266630A1 (en)	2010-10-21
CA2225278A1 (en)	1997-01-23
SI1312679T1 (sl)	2006-02-28
IL202448A0 (en)	2011-07-31
US8153138B2 (en)	2012-04-10
HUP9802217A3 (en)	1999-09-28
DK1312679T3 (da)	2006-01-09
TWI245075B (en)	2005-12-11
NO980026D0 (no)	1998-01-02
US20030035792A1 (en)	2003-02-20
DE69635172T2 (de)	2006-06-22
EE05138B1 (et)	2009-02-16
UA75411C2 (en)	2006-04-17
EP1312679A1 (en)	2003-05-21
EE200300332A (et)	2003-10-15
EE04753B1 (et)	2006-12-15
ES2249647T3 (es)	2006-04-01
JP4312260B2 (ja)	2009-08-12
US8197825B2 (en)	2012-06-12
AU721735B2 (en)	2000-07-13
EP1312679B1 (en)	2005-09-07
UA75410C2 (en)	2006-04-17
IL219528A0 (en)	2012-06-28
BR9609303B8 (pt)	2014-05-06
CZ424197A3 (cs)	1998-03-18
DE69635173D1 (de)	2005-10-13
EE04199B1 (et)	2003-12-15
CN1154742C (zh)	2004-06-23
DK1312678T3 (da)	2005-12-19
HK1009830A1 (en)	1999-06-11
ES2199294T3 (es)	2004-02-16
PL186857B1 (pl)	2004-03-31
EP0836648A1 (en)	1998-04-22
HU224061B1 (hu)	2005-05-30
US20070071770A1 (en)	2007-03-29
UA68327C2 (en)	2004-08-16
RU2198217C2 (ru)	2003-02-10

Publication	Publication Date	Title
PT836648E (pt)	2003-09-30	Virus mva recombinante e sua utilizacao
DE69332831T2 (de)	2004-01-29	Rekombinanter schweinepocken-virus
FI973309A0 (fi)	1997-08-12	Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi
NZ333975A (en)	2000-09-29	Recombinant swinepox virus
FR2702152B1 (fr)	1995-05-24	Virus recombinants et leur utilisation en thérapie génique.
HUP9802587A2 (hu)	1999-02-01	Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
MY134484A (en)	2007-12-31	Recombinant mva virus, and the use thereof
MY119381A (en)	2005-05-31	Recombinant mva virus, and the use thereof
MY157873A (en)	2016-07-29	Recombinant mva virus, and the use thereof